Literature DB >> 20889845

Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.

Emily Z Xu1, Crystal Kantores, Julijana Ivanovska, Doreen Engelberts, Brian P Kavanagh, Patrick J McNamara, Robert P Jankov.   

Abstract

Chronic pulmonary hypertension in infancy and childhood is characterized by a fixed and progressive increase in pulmonary arterial pressure and resistance, pulmonary arterial remodeling, and right ventricular hypertrophy and systolic dysfunction. These abnormalities are replicated in neonatal rats chronically exposed to hypoxia from birth in which increased activity of Rho-kinase (ROCK) is critical to injury, as evidenced by preventive effects of ROCK inhibitors. Our objective in the present study was to examine the reversing effects of a late or rescue approach to treatment with a ROCK inhibitor on the pulmonary and cardiac manifestations of established chronic hypoxic pulmonary hypertension. Rat pups were exposed to air or hypoxia (13% O(2)) from postnatal day 1 and were treated with Y-27632 (15 mg/kg) or saline vehicle by twice daily subcutaneous injection commencing on day 14, for up to 7 days. Treatment with Y-27632 significantly attenuated right ventricular hypertrophy, reversed arterial wall remodeling, and completely normalized right ventricular systolic function in hypoxia-exposed animals. Reversal of arterial wall remodeling was accompanied by increased apoptosis and attenuated content of endothelin (ET)-1 and ET(A) receptors. Treatment of primary cultured juvenile rat pulmonary artery smooth muscle cells with Y-27632 attenuated serum-stimulated ROCK activity and proliferation and increased apoptosis. Smooth muscle apoptosis was also induced by short interfering RNA-mediated knockdown of ROCK-II, but not of ROCK-I. We conclude that sustained rescue treatment with a ROCK inhibitor reversed both the hemodynamic and structural abnormalities of chronic hypoxic pulmonary hypertension in juvenile rats and normalized right ventricular systolic function. Attenuated expression and activity of ET-1 and its A-type receptor on pulmonary arterial smooth muscle was a likely contributor to the stimulatory effects of ROCK inhibition on apoptosis. In addition, our data suggest that ROCK-II may be dominant in enhancing survival of pulmonary arterial smooth muscle.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889845      PMCID: PMC5145304          DOI: 10.1152/ajpheart.00595.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  68 in total

1.  Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal?

Authors:  Kurt R Stenmark; Ivan F McMurtry
Journal:  Circ Res       Date:  2005-07-22       Impact factor: 17.367

Review 2.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

3.  Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases.

Authors:  T Ishizaki; M Uehata; I Tamechika; J Keel; K Nonomura; M Maekawa; S Narumiya
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

4.  Perinatal hypoxia increases hypoxic pulmonary vasoconstriction in adult rats recovering from chronic exposure to hypoxia.

Authors:  V Hampl; J Herget
Journal:  Am Rev Respir Dis       Date:  1990-09

5.  Endothelin-1 and O2-mediated pulmonary hypertension in neonatal rats: a role for products of lipid peroxidation.

Authors:  R P Jankov; X Luo; J Cabacungan; R Belcastro; H Frndova; S J Lye; A K Tanswell
Journal:  Pediatr Res       Date:  2000-09       Impact factor: 3.756

6.  Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.

Authors:  Masahiko Oka; Noriyuki Homma; Laimute Taraseviciene-Stewart; Kenneth G Morris; Donatas Kraskauskas; Nana Burns; Norbert F Voelkel; Ivan F McMurtry
Journal:  Circ Res       Date:  2007-03-01       Impact factor: 17.367

7.  PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.

Authors:  Anna R Hemnes; Ari Zaiman; Hunter C Champion
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-10-26       Impact factor: 5.464

8.  Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats.

Authors:  Guorong Lin; Graham P Craig; Lili Zhang; Violet G Yuen; Michael Allard; John H McNeill; Kathleen M MacLeod
Journal:  Cardiovasc Res       Date:  2007-03-14       Impact factor: 10.787

Review 9.  The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway.

Authors:  Yasuharu Sasaki; Masaaki Suzuki; Hiroyoshi Hidaka
Journal:  Pharmacol Ther       Date:  2002 Feb-Mar       Impact factor: 12.310

10.  Serial noninvasive assessment of progressive pulmonary hypertension in a rat model.

Authors:  John E Jones; Lisa Mendes; M Audrey Rudd; Giulia Russo; Joseph Loscalzo; Ying-Yi Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-07       Impact factor: 4.733

View more
  15 in total

1.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Authors:  Helen Christou; Ossama M Reslan; Virak Mam; Alain F Tanbe; Sally H Vitali; Marlin Touma; Elena Arons; S Alex Mitsialis; Stella Kourembanas; Raouf A Khalil
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

Review 2.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

3.  Enhanced NO-dependent pulmonary vasodilation limits increased vasoconstrictor sensitivity in neonatal chronic hypoxia.

Authors:  Joshua R Sheak; Laura Weise-Cross; Ray J deKay; Benjimen R Walker; Nikki L Jernigan; Thomas C Resta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

4.  Prolonged vasoconstriction of resistance arteries involves vascular smooth muscle actin polymerization leading to inward remodelling.

Authors:  Marius C Staiculescu; Edgar L Galiñanes; Guiling Zhao; Uri Ulloa; Minshan Jin; Mirza I Beig; Gerald A Meininger; Luis A Martinez-Lemus
Journal:  Cardiovasc Res       Date:  2013-02-14       Impact factor: 10.787

Review 5.  Rho kinase proteins--pleiotropic modulators of cell survival and apoptosis.

Authors:  Catharine A Street; Brad A Bryan
Journal:  Anticancer Res       Date:  2011-11       Impact factor: 2.480

Review 6.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

7.  Effect of chronic perinatal hypoxia on the role of rho-kinase in pulmonary artery contraction in newborn lambs.

Authors:  Arlin B Blood; Michael H Terry; Travis A Merritt; Demosthenes G Papamatheakis; Quintin Blood; Jonathon M Ross; Gordon G Power; Lawrence D Longo; Sean M Wilson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

Review 8.  Gestational Hypoxia and Developmental Plasticity.

Authors:  Charles A Ducsay; Ravi Goyal; William J Pearce; Sean Wilson; Xiang-Qun Hu; Lubo Zhang
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

9.  Rho-kinase inhibitor Y-27632 attenuates pulmonary hypertension in hyperoxia-exposed newborn rats.

Authors:  Hsiu-Chu Chou; Liang-Ti Huang; Tsu-Fu Yeh; Chung-Ming Chen
Journal:  Acta Pharmacol Sin       Date:  2013-08-26       Impact factor: 6.150

10.  Cross talk between autophagy and apoptosis in pulmonary hypertension.

Authors:  Yang Jin; Augustine M K Choi
Journal:  Pulm Circ       Date:  2012-10       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.